A clinical trial of creatine in ALS

Neurology

Volumn 63, Issue 9, 2004, Pages 1656-1661

  Shefner, J M ^a   Cudkowicz, M E ^b   Schoenfeld, D ^b   Conrad, T ^a   Taft, J ^a   Chilton, M ^a   Urbinelli, L ^b   Qureshi, M ^b   Zhang, H ^b   Pestronk, A ^c   Caress, J ^d   Donofrio, P ^d   Sorenson, E ^e   Bradley, W ^f   Lomen Hoerth, C ^g   Pioro, E ^h   Rezania, K ⁱ   Ross, M ^j   Pascuzzi, R ^k   Heiman Patterson, T ^l   Tandan, R ^m   Mitsumoto, H ⁿ   Rothstein, J ^o   Smith Palmer, T ^p   MacDonald, D ^p   Burke, D ^p   more..

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j UNIVERSITY OF KENTUCKY   (United States)

^k INDIANA UNIVERSITY   (United States)

^l DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^m UNIVERSITY OF VERMONT   (United States)

ⁿ Och Spine at New York Presbyterian Hospitals   (United States)

^o JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p ST FRANCIS XAVIER UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; PLACEBO;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARM MUSCLE; ARTICLE; CELL COUNT; CELL SIZE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT; GRIP STRENGTH; HUMAN; MAJOR CLINICAL STUDY; MOTOR UNIT; MUSCLE ISOMETRIC CONTRACTION; MUSCLE STRENGTH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPIRATORY FAILURE; SIDE EFFECT; SUPPLEMENTATION; TREATMENT OUTCOME; VOLUNTARY MOVEMENT;

EID: 8644289377     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000142992.81995.F0     Document Type: Article

References (39)

1. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
2. Trotti D, Rolfs A, Danbolt NC, et al. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter [published erratum appears in Nat Neurosci 1999;2:848]. Nat Neurosci 1999;2:427-433.
3. Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996;16:675-686.
4. Ferrante RJ, Browne SE, Shinobu LA, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997;69:2064-2074.
5. Robberecht W. Oxidative stress in amyotrophic lateral sclerosis. J Neurol 2000;247 Suppl 1:I1-6.
6. Rouleau GA, Clark AW, Rooke K, et al. SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis. Ann Neurol 1996;39:128-131.
7. Julien JP, Mushynski WE. Neurofilaments in health and disease. Prog Nucleic Acid Res Mol Biol 1998;61:1-23.
8. Julien JP, Couillard-Despres S, Meier J. Transgenic mice in the study of ALS: the role of neurofilaments. Brain Pathol 1998;8:759-769.
9. Masui Y, Mozai T, Kakehi K. Functional and morphometric study of the liver in motor neuron disease. J Neurol 1985;232:15-19.
10. Nakano K, Hirayama K, Terai K. Hepatic ultrastructural changes and liver dysfunction in amyotrophic lateral sclerosis. Arch Neurol 1987;44:103-106.
11. Sasaki S, Iwata M. Ultrastructural change of synapses of Betz cells in patients with amyotrophic lateral sclerosis. Neurosci Lett 1999;268:29-32.
12. Hirano A. Cytopathology in amyotrophic lateral sclerosis. Adv Neurol 1991;56:91-101.
13. Ro LS, Lai SL, Chen CM, Chen ST. Deleted 4977-bp mitochondrial DNA mutation is associated with sporadic amyotrophic lateral sclerosis: a hospital based case-control study. Muscle Nerve 2003;28:737-743.
14. Bruijn LI, Beal MF, Becher MW, et al. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS) - like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci USA 1997;94:7606-7611.
15. Dal Canto MC. Comparison of pathological alterations in ALS and a murine transgenic model: pathogenetic implications. Clin Neurosci 1995;3:332-337.
16. Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 1998;18:3241-3250.
17. Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995;14:1105-1116.
18. Hemmer W, Wallimann T. Functional aspects of creatine kinase in brain. Dev Neurosci 1993;15:249-260.
19. Beutner G, Ruck A, Riede B, Brdiczka D. Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implication for regulation of permeability transition by the kinases. Biochim Biophys Acta 1998;1368:7-18.
20. Schinder A, Olson E, Spitzer N, Montal M. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci 1996;16:6125-6133.
21. White R, Reynolds I. Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitotoxin exposure. J Neurosci 1996;16:5688-5697.
22. Lawler JM, Barnes WS, Wu G, et al. Direct antioxidant properties of creatine. Biochem Biophys Res Commun 2002;290:47-52.
23. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5:347-350.
24. Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline and creatine in a mouse model of ALS. Ann Neurol 2003;53:267-270.
25. Snow RJ, Turnbull J, da Silva S, et al. Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience 2003;119:661-667.
26. Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003;53:437-445.
27. Brooks B. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis." J Neurol Sci 1994;124(suppl):96- 107.
28. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61:456-464.
29. Andres PL, Thibodeau LM, Finison LJ, Munsat TL. Quantitative assessment of neuromuscular deficit in ALS. Neurol Clin 1987;5:125-141.
30. Andres PL, Hedlund W, Finison L, et al. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 1986;36:937-941.
31. Ohashi Y, Tashiro K, Itoyama Y, et al. [Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS (ALSFRS-R) Japanese version]. No To Shinkei 2001;53:346-355.
32. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999; 169:13-21.
33. Daube JR. Estimating the number of motor units in a muscle. J Clin Neurophysiol 1995;12:585-594.
34. Lomen-Hoerth C, Olney RK. Comparison of multiple point and statistical motor unit number estimation. Muscle Nerve 2000;23:1525-1533.
35. Olney RK, Yuen EC, Engstrom JW. Statistical motor unit number estimation: reproducibility and sources of error in patients with amyotrophic lateral sclerosis. Muscle Nerve 2000;23:193-197.
36. Shefner JM, Jillapalli D, Bradshaw DY. Reducing intersubject variability in motor unit number estimation. Muscle Nerve 1999;22:1457-1460.
37. Miller RG, Moore DH, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-848.
38. Osterberg R, Green M. Guidance for industry and reviewers: estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. Rockville, MD: US Department of Health and Human Services, Center from Drug Evaluation and Research, 2002.
39. Shefner J, Cudkowicz M, Zhang H, et al. The use of statistical MUNE in a multicenter clinical trial. Muscle Nerve 2004 (in press).